Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations

ir@sedanamedical.com Send Email

The Share

See More

Press Releases

Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031

Non-regulatory

Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has iss…

Key results of Sedana Medical’s paediatric study IsoCOMFORT published

Non-regulatory

Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study…

Sedana Medical AB’s Interim report January-September 2023

Regulatory

All-time-high Q3 sales and further steps towards ex-US profitability

View All Press Releases

Financial Calendar

Year-End Report 2023 15 February 2024 07:00
Annual Report 2023 15 April 2024 07:00

See More